{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:55:57Z","timestamp":1781679357366,"version":"3.54.5"},"reference-count":14,"publisher":"Norwegian Medical Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2017,3,21]]},"DOI":"10.4045\/tidsskr.16.0538","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T08:26:15Z","timestamp":1490257575000},"page":"456-8","source":"Crossref","is-referenced-by-count":1,"title":["A physically fit woman in her thirties with exertional dyspnoea"],"prefix":"10.4045","volume":"137","author":[{"given":"Martin Pr\u00f8ven","family":"Bogsrud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgeir","family":"Gr\u00e6sdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-7556","authenticated-orcid":false,"given":"Kjetil","family":"Retterst\u00f8l","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten B.","family":"Holven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"Nasir K, Budoff MJ, Blumenthal RS et al. Coronary Artery Calcification: Methods and Clinical Value. Hjerteforum 2008; 21: 25\u2009\u2013\u200936."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Vasc Med 2003; 8: 289\u2009\u2013\u200990. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15125495&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1191\/1358863x03vm518xx","DOI":"10.1191\/1358863x03vm518xx"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387\u2009\u2013\u200997. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26039521&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1410489","DOI":"10.1056\/NEJMoa1410489"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36: 2996\u2009\u2013\u20093003. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26330422&dopt=Abstract","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Raal FJ, Stein EA, Dufour R et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 331\u2009\u2013\u200940. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25282519&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0140-6736(14)61399-4","DOI":"10.1016\/j.jvs.2015.09.006"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Dangas GD, Claessen BE, Caixeta A et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56: 1897\u2009\u2013\u2009907. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21109112&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jacc.2010.07.028","DOI":"10.1016\/j.jacc.2010.07.028"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Narverud I, Retterst\u00f8l K, Iversen PO et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis 2014; 235: 299\u2009\u2013\u2009309. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24908240&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.atherosclerosis.2014.05.917","DOI":"10.1016\/j.atherosclerosis.2014.05.917"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Mundal L, Sarancic M, Ose L et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992\u2009\u2013\u20092010. J Am Heart Assoc 2014; 3: e001236. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25468658&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/JAHA.114.001236","DOI":"10.1161\/JAHA.114.001236"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Krogh HW, Mundal L, Holven KB et al. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur Heart J 2016; 37: 1398\u2009\u2013\u2009405. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26586781&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093\/eurheartj\/ehv602","DOI":"10.1093\/eurheartj\/ehv602"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Khera AV, Won HH, Peloso GM et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 2016; 67: 2578\u2009\u2013\u200989. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=27050191&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jacc.2016.03.520","DOI":"10.1016\/j.jacc.2016.03.520"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19001495&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136\/bmj.a2423","DOI":"10.1136\/bmj.a2423"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Langslet G, Bogsrud MP, Halvorsen I et al. Long-term follow-up of young adults with familial hypercholesterolemia after participation in clinical trials during childhood. J Clin Lipidol 2015; 9: 778\u2009\u2013\u200985. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26687698&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.jacl.2015.08.008","DOI":"10.1016\/j.jacl.2015.08.008"},{"key":"ref=13","unstructured":"\u00d8stli LOL, Gr\u00e6sdal A. Store regionale ulikheter i\u00a0tilbudet til pasienter med alvorlige lipidforstyrrelser. Hjerteforum 2009; 22: 37\u2009\u2013\u200946."},{"key":"ref=14","unstructured":"Nasjonal kompetansetjeneste for famili\u00e6r hyperkolesterolemi. www.NKTforFH.no (21.2.2017)."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["En veltrent kvinne i 30-\u00e5rene med anstrengelsesdyspn\u00e9"],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:28:57Z","timestamp":1781677737000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2017\/03\/noe-laere-av\/en-veltrent-kvinne-i-30-arene-med-anstrengelsesdyspne"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3,21]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.16.0538","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]}}}